Search results for: drug prices

Speak Out Rheum: Attacks Against Healthcare Providers in China Spur Chinese Rheumatologists to Heal Strained Doctor–Patient Relationships Through Technology

Qiang Tong, MD | September 1, 2013

The Chinese SLE treatment and research group (CSTAR) database serves as an information resource about lupus, rheumatoid arthritis, and systemic sclerosis, and a communication platform between health-care providers and rheumatology patients

Global Perspective

Bryn Nelson, PhD | August 1, 2011

Healthcare policy varies by country, but U.S. lags in key areas

Let’s Get Personal

David S. Pisetsky, MD, PhD | May 1, 2009

Finding cost-effective solutions in the quest for personalized medicine

Medicare Switch to ASP Pricing Reduces Part B Spending

Staff | April 1, 2007

The Medicare Payment Advisory Commission (MedPAC) reported to Congress in January that Medicare’s switch to a payment method known as ASP, or Average Sale Price, has reduced spending on drugs in the Medicare Part B program. This system reflects actual market spending, rather than wholesale prices.

Medicare D-lemmas

Ann Kepler | January 1, 2007

Rheumatologists and patients report mixed experiences with the new prescription drug benefit

Rheumatology in China: An American Fellow’s Experience

Audrey Liu, MD | July 9, 2025

An American rheumatology fellow explores the differences& similarities between the U.S. & Chinese health systems through a visit toa hospital inHangzhou, China.

Incarcerated Individuals with Rheumatic Conditions

Katherine Terracina, MD, & Prajakta P. Masurkar, PhD | June 8, 2025

In addition to the impediments to consistent, high-quality care suffered by all incarcerated individuals, incarcerated patients with rheumatic disease face challenges specific to the treatment, management & monitoring of rheumatic conditions.

Experts Highlight Key Issues Impairing Access to Care

Thomas R. Collins | December 12, 2023

Speakers discussed common payer practices and policies that rheumatologists must navigate to secure and maintain appropriate care for their patients, including pharmacy benefit managers and prior authorization.

Marching to the Biosimilar Beat: Questions on Rollout Remain

Ruth Jessen Hickman, MD | September 7, 2023

The availability of biosimilars for the treatment of patients with rheumatic diseases exploded in 2023. Here’s where we stand and what to expect going forward.

Mark Cuban: Mixing Up the Pharmaceutical Landscape

Catherine Kolonko | April 7, 2023

The Mark Cuban Cost Plus Drug Co. (CPD) launched in January 2022 to distribute and home deliver prescribed generic medications to consumers. The Texas-based business seeks to reduce the prices of generic drugs by leapfrogging financial negotiators and going straight to drug companies for supply, according to a news release.1 “It’s crazy that medications are…